Positive Predictive Value of ICD-10 Diagnosis Codes for COVID-19
Overview
Authors
Affiliations
Purpose: To examine the positive predictive value (PPV) of International Classification version 10 (ICD-10) diagnosis codes for Coronavirus disease 2019 (COVID-19).
Patients And Methods: Medical record review of all patients assigned a diagnosis code of COVID-19 (DB342A or DB972A) at six Danish departments of infectious diseases from February 27 through May 4, 2020. Confirmed COVID-19 diagnosis was defined as either: 1) definite, a positive polymerase chain reaction (PCR) for severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) on a respiratory sample combined with symptoms suggestive of COVID-19: 2) probable, clinical presentation of COVID-19 without detection of SARS-CoV-2 and no alternative diagnoses considered more likely; or 3) possible, clinical presentation of COVID-19 without detection of SARS-CoV-2, and the patient was discharged or deceased before further investigations were carried out. We computed the PPV with 95% confidence intervals (CI) as the number of patients with confirmed (i.e., definite, probable, and possible) COVID-19 divided by the number of patients assigned a diagnosis code for COVID-19.
Results: The study included 710 patients with a median age of 61 years (interquartile range [IQR] 47-74) and 285/710 (40%) were female. COVID-19 was confirmed in 706/710 (99%) with 705/710 (99%) categorized as definite, 1/710 (0.1%) as probable, and 0 patients as possible COVID-19. The diagnosis was disproven in 4/710 (0.6%) patients who were hospitalized due to bacterial pneumonia (n = 2), influenza (n = 1), and urinary tract infection (n = 1). The overall PPV for COVID-19 was 99% (95% CI 99-100) and remained consistently high among all subgroups including sex, age groups, calendar period, and stratified by diagnosis code and department of infectious diseases (range 97-100%).
Conclusion: The overall PPV of diagnosis codes for COVID-19 in Denmark was high and may be suitable for future registry-based prognosis studies of COVID-19.
Patel A, Payne A, Currie D, Franceschini T, Gensheimer A, Lutgring J J Am Med Dir Assoc. 2025; 26(3):105440.
PMID: 39788487 PMC: 11890922. DOI: 10.1016/j.jamda.2024.105440.
Moura C, Neville A, Liao F, Wen B, Razak F, Roberts S CMAJ Open. 2023; 11(5):E982-E987.
PMID: 37875313 PMC: 10610021. DOI: 10.9778/cmajo.20230033.
Whittaker R, Toikkanen S, Dean K, Lyngstad T, Buanes E, Klovstad H Euro Surveill. 2023; 28(33).
PMID: 37589591 PMC: 10436689. DOI: 10.2807/1560-7917.ES.2023.28.33.2200888.
Andersen A, Gribsholt S, Pedersen L, Thomsen R, Benfield T, Sogaard O Obes Sci Pract. 2023; 9(4):355-363.
PMID: 37546282 PMC: 10399535. DOI: 10.1002/osp4.659.
Gronkjaer C, Christensen R, Kondziella D, Benros M Nat Commun. 2023; 14(1):4235.
PMID: 37454151 PMC: 10349860. DOI: 10.1038/s41467-023-39973-6.